Innovation, evidence gaps and solutions for children

This session explored innovative approaches addressing evidence gaps in paediatric development and improving the generation and use of evidence for children. Discussions touched on translational science, regulatory pathways, real-world evidence, digital technologies, biomarkers and precision medicine, with a focus on how these approaches can be adapted to the specific needs and challenges of paediatric research. Perspectives and priorities of children and young people were considered as an important component in identifying evidence needs and developing research solutions that are meaningful and relevant to them.

Panellists:

Giovanni Migliaccio

Read more

Giovanni Migliaccio is the Scientific Director of the Consorzio per Valutazioni Biologiche e Farmacologiche, (CVBF Pavia, IT) and a Senior Advisor for the European Translational Medicine Research Infrastructure (EATRIS, Amsterdam NL). He obtained a PhD in Biological science in 1977 at the University of Naples (Italy). His interest in science developed around stem cell proliferation and differentiation mechanisms. He spent two years as Post Doc at the University of Washington (Seattle, WA) and 5 years as Associate Scientist at the New York Blood Center (New York, NY). He continued his studies at the Istituto Superiore di Sanità (ISS) in Rome resulting in more than 150 scientific publications over the years. He is involved in the regulatory aspects of using cultured cells as part of human therapies and acts as an expert for the Italian government in the area of Cell and Gene Therapies. He is also an expert for these products for the European Medicines Agency (EMA). He was also the Chair of the CTP group at the European Department for Quality of Medicines (EDQM) from 2010 to 2018.

Marek Migdal

Read more

Marek Migdał, MD, PhD. Pediatrician and pulmonologist. CEO of the Children’s Memorial Health Institute in Warsaw. Member of the PDCO EMA. 

Madlen Gazarian

Read more

Madlen Gazarian is an Australian and Canadian trained Specialist Academic Physician with a unique mix of cross-disciplinary clinical and scientific expertise, experience and qualifications in Clinical Pharmacology and Therapeutics, Clinical Epidemiology and Health Services Research, Pharmacoepidemiology and Pharmacovigilance and Paediatric Medicine.
She is currently an Honorary Professor in the School of Clinical Medicine, Faculty of Medicine and Health at the University of New South Wales (UNSW) Sydney and was previously the Founding Head of the Paediatric Therapeutics Program in the School of Women’s and Children’s Health, UNSW and Sydney Children’s Hospital, Randwick, in Sydney Australia.

Professor Gazarian is a recognised national and international leader specialising in innovative, collaborative and impactful approaches to improving the development and appropriate use of medicines, with focus on the paediatric population. Her research and scholarly work focus on Evidence-Based Therapeutic decision-making, Quality Use of Medicines (Rational Use of Medicines) and Medicines Safety evaluation and improvement, including through the development and application of methodologies for optimised use and generation of Real-World Evidence (RWE).

Annalisa Landi

Read more

Researcher at Fondazione per la Ricerca Farmacologica Gianni Benzi -ETS (FGB) in Bari, Italy. Ethics Advisor of TheRacil project and Member of the Steering Group of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

PharmD, II level post-graduate Master in Regulatory Sciences “G.Benzi”, internship trainee at Leiden University Medical Center in the FAIR team.

Involved in scientific, ethical and regulatory activities particularly related to clinical studies, data protection and confidentiality, plan and management of patient registries and medicine databases,
health data and accessibilities issues, gender equality and inclusiveness.

Collaboration in several national and international projects dealing with ethics in biomedical research.

Giuseppe Pontrelli

Read more

Giuseppe Pontrelli, MD, PhD, MSc, Head of Clinical Trial Quality Team at Bambino Gesù Children Hospital,  is a physician-researcher with specific training and experience in epidemiology, vaccine development, infectious diseases, and clinical trial methodology. He graduated in Medicine and Surgery at the University of Pisa, completed a residency in Hygiene and Public Health at the University of Rome Tor Vergata, and holds a PhD in Clinical Trial Methodology and a Master’s degree in Paediatric Drug Development at at the University of Rome Tor Vergata.

His early career included original research on gene therapy for cardiovascular diseases and on new vaccines, as well as field epidemiological surveys of epidemics. He provided medical care and conducted clinical research in children with HIV infection, with a particular interest in new antiretroviral drugs and in the systemic and cardiovascular effects of HIV. He has served as an expert for the European Medicines Agency (EMA), and has worked on  clinical database analysis.

He has contributed to the birth of  the Clinical Trial Centre of the Bambino Gesù Children’s Hospital, acting as investigator and/or study coordinator in more than 400 Phase I–IV trials across paediatric neurology, psychiatry, cardiology, rheumatology, pulmonology, infectious diseases, and metabolism. He has also authored protocols for paediatric studies and several scientific papers.

Since 2022 he has led the Clinical Trial Quality Team, whose staff provides continuous support to Principal Investigators before, during, and after the conduct of non-profit paediatric clinical studies on drugs, vaccines, and medical devices.

Viviana Giannuzzi

Read more

PharmD, PhD in cellular biochemistry and pharmacology, post-graduate master in Clinical Research of Medicines.
My main areas of expertise are: ethics and regulatory, for rare and paediatric diseases, informed consent and assent, health data processing for research purposes, European medicine regulatory procedures.

Currently, I coordinate the Research & Innovation Department of Fondazione per la Ricerca Farmacologica Gianni Benzi and participate in international and national research projects and consortia; in most of them, I lead the ethics and regulatory activities. I am member of the Paediatric Committee, European Medicine Agency (EMA), as delegate of the European Commission to represent patient organisations.

I am member of international groups: EMA Patients and Consumers Working Party (PCWP);
European Platform for Regulatory Science Research, INHERENT (International Hemoglobinopathy Research Network), TEDDY network (The European Network of Excellence for Paediatric Research), EURORDIS Therapeutic Action Group, Regulatory Ethics workstream of GA4GH, EPTRI (European Paediatric Transnational Research Infrastructure).

I also joined paediatric working groups, e.g. Ethics Working Group of EnprEMA; Working Group on Rare Cancers of ECPC (European Cancer Patient Coalition); paediatric pharmacology Working Group of the Italian Society of Pharmacology.
Author/co-author of peer reviewed publications and abstracts, reviewer for indexed journals and speaker at national and international congresses/meetings in the relevant fields of expertise.

Solange Corriol-Rohou

Read more

Dr SOLANGE CORRIOL-ROHOU, MD, PHD       

Pulmonologist and immuno-allergist by training, Solange had to leave AstraZeneca R&D in May 2025, after 21 years, while being a Sr. Global Regulatory Affairs & Policy Director. Over the past 20 years, moving from the French Medicines Agency (AFSSAPS)/European Medicines Agency (EMA) and academia to the pharma industry, she gained strategic experience in respiratory, rheumatology, inflammation and oncology drug development.         
Previously, in her role as the chair of the EFPIA (European Federation of Pharmaceutical Industries and Associations) CDEG (Clinical Development Expert Group) until 2022, Solange organized jointly with the EMA several workshops (e.g. Modelling & Simulation, Paediatric Extrapolation, Adaptive Design). She is still quite active within EFPIA, ICH, the ACCELERATE Paediatric oncology platform and EnprEMA. She is passionate about paediatric drug development and drug development optimisation for rare diseases.    
She has also experience working in public-private partnership projects (e.g., IMI PROactive in COPD, ADAPT SMART, U-BIOPRED, Get Real, Trials@Home and MOBILISE-D). In 2022, on behalf of EFPIA, she proposed a project to IHI (Innovative Health Initiative) as part of the Rare Disease Moonshot Initiative: IHI RealiseD, for which she was initially the project lead. She is currently actively involved in ERDERA and some Horizon Europe rare disease projects, such as DREAMS and RESTORE VISION.
Solange is currently working as a consultant and collaborates with VOISIN Consulting.  
As a board member of EFGCP (European Forum for Good Clinical Practice), involved in the EFGCP Children Medicines Working Party, she is used to participate in the organisation of the EFGCP Annual Paediatric conference, has been actively involved in the drafting and the implementation of the Good Lay Summary Practice Guideline, and is currently involved in the EFGCP-EFPIA cross border initiative aimed at facilitating patients access to clinical trials in any other European countries. She recently joined TEDDY and EPTRI.
She has published over 100 scientific papers in peer-reviewed journals and is a member of the Editorial Board of the CPT Journal